These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12125243)

  • 1. [Adverse effects of multi-drug therapy in patients with tuberculosis and ways of their correction].
    Gel'berg IS; Vol'f SB; Vrublevskaia NI; Pigalkova EN; Krotkova EN; Shevchuk DV; Avlasenko VS
    Probl Tuberk; 2002; (4):12-6. PubMed ID: 12125243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current aspects of pathogenetic therapy in tuberculosis].
    Balasaniants GS; Sukhanov DS
    Ter Arkh; 2011; 83(8):21-4. PubMed ID: 21961327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathogenetic therapy of pulmonary tuberculosis in adolescents].
    Pavlova MV
    Probl Tuberk; 1994; (3):19-21. PubMed ID: 7937663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of antioxidants on lipid peroxidation and on liver function in patients with pulmonary tuberculosis].
    Skakun NL; Blikhar EI
    Farmakol Toksikol; 1986; 49(5):112-4. PubMed ID: 3770163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antioxidant treatment of pulmonary tuberculosis in patients with chronic alcoholism].
    Burnusus ZI
    Probl Tuberk; 1992; (5-6):28-30. PubMed ID: 1409509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy of destructive pulmonary tuberculosis with antioxidants and antihypoxic agents].
    Savula MM; Kravchenko NS; Poznanskiĭ AI
    Probl Tuberk; 1993; (5):18-20. PubMed ID: 8295877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antioxidant effectiveness in preventing and eliminating the side effects of antibacterial preparations in pulmonary tuberculosis patients].
    Starostenko EV; Andrzheiuk NI; Salpagarov AM
    Probl Tuberk; 1987; (10):34-7. PubMed ID: 3422950
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pathogenetic therapy in pulmonary tuberculosis].
    Starostenko EV
    Probl Tuberk; 1989; (5):22-6. PubMed ID: 2748555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adverse reactions of antituberculous agents, especially about its onset and duration].
    Yamada H; Yasuoka A; Sasayama K; Doutsu Y; Hayashi T; Kohno S; Yamaguchi K; Hirota M; Hara K
    Kekkaku; 1990 Sep; 65(9):563-8. PubMed ID: 2232434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The efficacy of antioxidant therapy in patients with tuberculosis of the lungs and the correction of lipid peroxidation processes].
    Safarian MD; Karagezian KG; Karapetian ET; Avanesian NA
    Probl Tuberk; 1990; (5):40-4. PubMed ID: 2388892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antioxidants--effective pathogenetic agents in the combined therapy of pulmonary tuberculosis].
    Gur'eva IG; Starostenko EV; Narovlianskaia SE
    Ter Arkh; 1987; 59(7):72-4. PubMed ID: 3672365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Individual approaches to complex treatment of disseminated tuberculous processes in adolescents].
    Gergert VIa; Rusakova LI
    Probl Tuberk Bolezn Legk; 2006; (8):33-7. PubMed ID: 17002056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients].
    Khodashova ML; Iuditskiĭ MV; Semenova OV
    Probl Tuberk Bolezn Legk; 2004; (3):26-8. PubMed ID: 15338896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficiency treatment of new cases of destructive pulmonary tuberculosis in the presence of concurrent iron deficiency anemia].
    Voloshina VV; Fomicheva NI
    Probl Tuberk; 2002; (2):10-2. PubMed ID: 11899794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complex treatment of destructive pulmonary tuberculosis].
    Shul'ga IA; Znosenko VA; Sukhorukova IS; Davydova GN; Surovtseva EIa; Shlapakova MA; Pelipas IG
    Probl Tuberk Bolezn Legk; 2003; (7):29-31. PubMed ID: 12939873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frequency and pattern of adverse reactions due to treatment of patients with pulmonary tuberculosis with antitubercular reserve drugs].
    Chukanov VI; Kaminskaia GO; Livchane E
    Probl Tuberk Bolezn Legk; 2004; (10):6-10. PubMed ID: 15568310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in the patients' mental status in the tolerability of antituberculous drugs].
    Mordyk AV; Briukhanova NS; Kazakov AV
    Probl Tuberk Bolezn Legk; 2009; (3):38-42. PubMed ID: 19455986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correction of bronchial obstructive syndrome and antituberculous drugs-induced eosinophilia in patients with pulmonary tuberculosis by using plasmapheresis].
    Shmelev EI; Stepanian IE
    Probl Tuberk; 1996; (6):57-60. PubMed ID: 9019774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.